Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 28 clinical trials
None
Study of Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy

The purpose of this study is to determine if LCZ696 is safe, tolerable and can improve exercise capacity (via improved peak VO2) in non-obstructive HCM patient population over the course of 50 weeks of treatment.

nt-probnp
exercise test
cpet
hypertrophy
hypertrophic obstructive cardiomyopathy
  • 26 views
  • 28 Oct, 2021
  • 19 locations
None
Changes in NT-proBNP and Outcomes Safety and Tolerability in HFpEF Patients With Acute Decompensated Heart Failure (ADHF) Who Have Been Stabilized During Hospitalization and Initiated In-hospital or Within 30 Days Post-discharge (PARAGLIDE-HF)

The purpose of this study is to assess the effect of sacubitril/valsartan (LCZ696) vs. valsartan on changes in NT-proBNP and outcomes, safety and tolerability in patients with HFpEF (left

  • 38 views
  • 08 Jul, 2021
  • 94 locations
None
Pharmacodynamic Effects of Sacubitril/Valsartan on Natriuretic Peptides Angiotensin and Neprilysin

The study measure multiple neurohormones in patients with heart failure being treated with Sacubitril/Valsartan in increasing doses over an 8 week period.

angiotensin
sacubitril/valsartan
chronic heart failure
ejection fraction
  • 5 views
  • 23 Jan, 2021
  • 1 location
None
Influence of Sacubitril/Valsartan on Autonomic Cardiac Nervous System in Heart Failure Patients: an Exploratory Study

Sacubitril/valsartan is an angiotensin receptor neprilysin inhibitor with the ability to reduce myocardial hypertrophy, cardiac remodeling and cardiorenal fibrosis. The compound is also believed

  • 0 views
  • 26 Jan, 2021
  • 1 location
None
Protecting With ARNI Against Cardiac Consequences of Coronavirus Disease 2019

The purpose of this study is to determine the effect of sacubitril/valsartan versus placebo on markers of cardiac injury, structure, and function among patients who recovered from acute COVID-19

  • 0 views
  • 23 Aug, 2021
  • 1 location
None
Safety and Efficacy of ARNI After LVAD ImplanT (SEAL-IT) Study

The purpose of the study is to evaluate how well tolerated and effective an angiotensin receptor-neprilysin inhibitor (sacubitril-valsartan) is in patients with contemporary durable continuous

  • 2 views
  • 19 Jun, 2021
  • 1 location
None
ARNI in Asymptomatic Patients With Elevated Natriuretic Peptide and Elevated Left Atrial Volume Index eLEvation

The purpose of this study is to determine whether LCZ696 (valsartan/sacubitril) is safe and has beneficial effects on the heart and blood vessels in patients with high blood pressure and/or

diabetes
hypertension
heart failure
sacubitril
natriuretic peptide
  • 0 views
  • 08 Nov, 2020
  • 1 location
None
Effect of Angiotensin-Neprilysin Inhibition (ARNI) on Prognosis of Chronic Heart Failure

This study is a randomized controlled multicenter clinical trial, in which about 340 patients with newly diagnosed or prior diagnosed chronic heart will be recruited. Patients will be randomly divided into Angiotensin-Neprilysin Inhibition (ARNI) group and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ACEI/ARB) group. All-cause death, cardiac death and …

nt-probnp
ace inhibitor
enalapril
angiotensin ii receptor antagonist
angiotensin
  • 0 views
  • 23 Jan, 2021
  • 1 location
None
Cost and Shared Decision-Making for Heart Failure

This study is designed to understand the impact of providing patient-specific cost at the time of the clinical encounter on decision-making for heart failure medications. The researchers will provide patients with heart failure with patient-specific cost information for non-generic heart failure medications. This cost information will be populated onto a …

  • 0 views
  • 23 Jun, 2021
  • 4 locations
None
Sacubitril/Valsartan vs Lifestyle in Hypertrophic Cardiomyopathy

neprilysin inhibitor sacubitril / valsartan) interventions in patients with HCM. The Aim is to examine whether these interventions improve functional capacity, clinical phenotypic characteristics, and

neprilysin inhibitor
cardiovascular disease
heart failure
angiotensin
hypertrophy
  • 0 views
  • 06 Oct, 2021
  • 5 locations